"Nov. 6, 2012 -- The FDA has approved Pfizer's Xeljanz (tofacitinib), a first-of-its-kind treatment for rheumatoid arthritis.
Xeljanz is approved for use by patients not helped by methotrexate, the usual first treatment for RA. It's a "...
ARAVA is indicated for the treatment of adults with active rheumatoid arthritis (RA).
DOSAGE AND ADMINISTRATION
The recommended dosage of ARAVA is 20 mg once daily. Treatment may be initiated with or without a loading dose, depending upon the patient's risk of ARAVA-associated hepatotoxicity and ARAVA-associated myelosuppression. The loading dosage provides steady-state concentrations more rapidly.
- For patients who are at low risk for ARAVA-associated hepatotoxicity and ARAVA-associated myelosuppression the recommended ARAVA loading dosage is 100 mg once daily for 3 days. Subsequently administer 20 mg once daily.
- For patients at high risk for ARAVA-associated hepatotoxicity (e.g., those taking concomitant methotrexate) or ARAVA-associated myelosuppression (e.g., patients taking concomitant immunosuppressants), the recommended ARAVA dosage is 20 mg once daily without a loading dose [see WARNINGS AND PRECAUTIONS].
The maximum recommended daily dosage is 20 mg once per day. Consider dosage reduction to 10 mg once daily for patients who are not able to tolerate 20 mg daily (i.e., for patients who experience any adverse events listed in Table 1).
Monitor patients carefully after dosage reduction and after stopping therapy with ARAVA, since the active metabolite of leflunomide, teriflunomide, is slowly eliminated from the plasma [see CLINICAL PHARMACOLOGY]. After stopping ARAVA treatment, an accelerated drug elimination procedure is recommended to reduce the plasma concentrations of the active metabolite, teriflunomide [see WARNINGS AND PRECAUTIONS]. Without use of an accelerated drug elimination procedure, it may take up to 2 years to reach undetectable plasma teriflunomide concentrations after stopping ARAVA [see CLINICAL PHARMACOLOGY].
Evaluation And Testing Prior To Starting ARAVA
Prior to starting ARAVA treatment the following evaluations and tests are recommended:
- Evaluate patients for active tuberculosis and screen patients for latent tuberculosis infection [see WARNINGS AND PRECAUTIONS]
- Laboratory tests including serum alanine aminotransferase (ALT); and white blood cell, hemoglobin or hematocrit, and platelet counts [see WARNINGS AND PRECAUTIONS]
- For females of reproductive potential, pregnancy testing [see WARNINGS AND PRECAUTIONS]
- Check blood pressure [see WARNINGS AND PRECAUTIONS]
Dosage Forms And Strengths
ARAVA Tablets are available in three strengths:
- Tablets: 10 mg, supplied as white, round film-coated tablet embossed with “ZBN” on one side
- Tablets: 20 mg, supplied as light yellow, triangular film-coated tablet embossed with “ZBO” on one side
- Tablets: 100 mg, supplied as white, round film-coated tablet embossed with “ZBP” on one side
Storage And Handling
ARAVA® (leflunomide) Tablets
|10 mg||30 count bottle||0088-2160-30||White, round film-coated tablet embossed with “ZBN” on one side.|
|20 mg||30 count bottle||0088-2161-30||Light yellow, triangular film-coated tablet embossed with “ZBO” on one side.|
|100 mg||3 count blister pack||0088-2162-33||White, round film-coated tablet embossed with “ZBP” on one side.|
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Protect from light.
sanofi-aventis U.S. LLC Bridgewater, NJ 08807. Revised: Sep 2015.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/15/2015
Additional Arava Information
Arava - User Reviews
Arava User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options